DVL Stock Overview
Acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Alliance Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.50 |
| 52 Week High | UK£0.55 |
| 52 Week Low | UK£0.30 |
| Beta | 0.64 |
| 11 Month Change | -3.85% |
| 3 Month Change | 18.48% |
| 1 Year Change | 17.37% |
| 33 Year Change | -57.27% |
| 5 Year Change | -44.75% |
| Change since IPO | -54.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| DVL | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.4% | -5.0% | -1.3% |
| 1Y | 17.4% | -22.0% | 7.4% |
Return vs Industry: DVL exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: DVL exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| DVL volatility | |
|---|---|
| DVL Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DVL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DVL's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 290 | Nick Sedgwick | www.alliancepharmaceuticals.com |
Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
Alliance Pharma plc Fundamentals Summary
| DVL fundamental statistics | |
|---|---|
| Market cap | €295.96m |
| Earnings (TTM) | -€40.41m |
| Revenue (TTM) | €220.38m |
1.3x
P/S Ratio-7.3x
P/E RatioIs DVL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVL income statement (TTM) | |
|---|---|
| Revenue | UK£183.15m |
| Cost of Revenue | UK£74.33m |
| Gross Profit | UK£108.82m |
| Other Expenses | UK£142.40m |
| Earnings | -UK£33.58m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.062 |
| Gross Margin | 59.42% |
| Net Profit Margin | -18.34% |
| Debt/Equity Ratio | 46.0% |
How did DVL perform over the long term?
See historical performance and comparison